Novavax reported $-345829000 in EBIT for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Adma Biologics ADMA:US $ -15581230 416.98K
Agenus AGEN:US $ -66395000 25.02M
AstraZeneca AZN:LN 1.4B 366M
Astrazeneca AZN:US 1.4B 366M
Biocryst Pharmaceuticals BCRX:US $ -29582000 21.8M
BioSpecifics Technologies BSTC:US 651.19K 676.28K
Dynavax Technologies DVAX:US $ 9.68M 19.34M
Genocea Biosciences GNCA:US $ -14546000 2.12M
GlaxoSmithKline GSK:LN 1.96B 281M
Kindred Biosciences KIN:US -8544000 622K
Mannkind MNKD:US $ -9031000 998K
Merk MRK:US $ 3930M 332M
Minerva Neurosciences NERV:US $ -8963290 1.46M
Moderna Inc MRNA:US 3.06B 1.8B
Novartis NVS:US 3.4B 415M
Novavax NVAX:US $ -345829000 137.2M
Pain Therapeutics PTIE:US $ -5138000 1.6M
Peregrine Pharmaceuticals PPHM:US $ 6.93M 3.84M
Pfizer PFE:US $ 6662M 905M
Sarepta Therapeutics SRPT:US $ -167574000 25.71M
Tg Therapeutics TGTX:US $ -77492000 11.71M